Information  X 
Enter a valid email address

Renishaw PLC (RSW)

  Print          Annual reports

Thursday 21 October, 2021

Renishaw PLC

Trading Statement

RNS Number : 7378P
Renishaw PLC
21 October 2021

Renishaw plc

Trading update

21 October 2021


Renishaw plc, the global provider of manufacturing technologies, analytical instruments and medical devices, publishes this trading update for the three months ended 30 September 2021. It contains unaudited information that covers the first quarter of the financial year and the period since.


Trading activity



3 months to 30 September 2021

3 months to 30 September 2020






Manufacturing technologies




Analytical instruments and medical devices




Total Revenue







Adjusted* Profit before tax




Statutory Profit before tax






Group revenue for the first quarter of the current financial year was £157.8m, compared to £116.9m for the corresponding period last year. We have experienced strong revenue growth in all our regions following an improvement to global macroeconomic conditions over the last year.


In our Manufacturing technologies business (formerly Metrology) revenue amounted to £148.5m, compared to £111.2m last year, with the strong growth driven largely by demand from the semiconductor and electronics markets. In our Analytical instruments and medical devices business (formerly Healthcare) revenue was £9.3m, compared with £5.7m last year.


Adjusted* profit before tax for the first quarter amounted to £41.7m compared with £18.3m last year and the statutory profit before tax amounted to £39.3m (2020: £28.2m).


Financial position  


The Group balance sheet remains strong with net cash and bank deposit balances of £234.8m at 30 September 2021 (30 June 2021: £215.0m).




The 2022 financial year has started with a strong first quarter and we currently have a record order book. We expect demand from the semiconductor and electronics sectors to remain strong and that there will continue to be a recovery in the machine tool and co-ordinate measuring machine markets. In our Analytical instruments and medical devices markets, we have seen confidence return and capital expenditure projects released.


The Board continues to be confident in our long-term prospects, due to our strong financial position, the high quality of our people, our innovative product pipeline, extensive global sales and marketing presence and relevance to high-value manufacturing.

The results for the half year ending 31 December 2021 are expected to be released on 3 February 2022.

Will Lee

Allen Roberts


Chief Executive

Group Finance Director



21 October 2021



Renishaw plc

Registered office

New Mills, Wotton-under-Edge, Gloucestershire, GL12 8JR

Registered number


Telephone number

+44 (0) 1453 524524





Adjusted profit before tax


The adjustment to statutory profit relates to the accounting treatment of certain forward currency contracts used as hedging instruments which do not qualify for hedge accounting as they do not meet the hedge effectiveness criteria set out in the International Accounting Standard IFRS 9 'Financial Instruments'.


The Board deems that the adjusted profit before tax better reflects the underlying performance of the Group. The following table reconciles statutory profit before tax to adjusted profit before tax:




3 months to 30 September 2021

3 months to 30 September 2020





Statutory profit before tax




Fair value (gains)/losses on financial instruments not eligible for hedge accounting

  - reported in revenue



  - reported in (gains)/losses from the fair value of financial instruments




Adjusted profit before tax




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t